| Name | Gatifloxacin hydrochloride |
| Description | Gatifloxacin hydrochloride (AM-1155 hydrochloride) is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. |
| Animal Research | Heptanol-induced corneal ulcers in New Zealand White rabbits (n = 41; 8 females/group) were inoculated with 10(6) CFU of Pseudomonas aeruginosa. Gatifloxacin 0.3% dosing varied among 4 groups with frequencies of 16-48 doses/day (days 1-2), 3-16 doses/day (days 3-7), and maintenance dosing of 3-4 doses/day (days 8-22). Ciprofloxacin 0.3% was administered as labeled for corneal ulcers, with 44 doses on day 1, 16 doses on day 2, and 4 doses/day on days 3-21[1] |
| In vivo | All eyes showed evidence of infection by 48 hours postinoculation with 36 of 41 eyes (87.8%) exhibiting moderate-to-severe keratitis. All eyes exhibited corneal healing by day 15, with no significant differences among groups. Three of 4 groups receiving gatifloxacin tended to have smaller fluorescein retention area scores than did the ciprofloxacin group. No eyes tested positive for Pseudomonas at the end of the study. No corneal precipitates were found following as many as 48 doses/day of gatifloxacin[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 10 mg/mL (24.28 mM), Sonication is recommended.
DMSO : 4.12 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | Antibiotic | AM1155 | BMS-206584 | E. coli,?Pseudomonas aeruginosa,?Micrococcus luteus | Gatifloxacin | PD-135432 | BMS 206584 | conjunctivitis | N. brasiliensis | actinomycetoma | Gatifloxacin hydrochloride | Inhibitor | S. aureus | Bacterial | inhibit | hypoglycemia | Topoisomerase | AM 1155 | Gatifloxacin Hydrochloride | diabetic | PD135432 | hyperglycemia | PD 135432 | BMS206584 | AM-1155 |
| Inhibitors Related | Neomycin sulfate | Dimethyl sulfoxide |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
